Pharmaceutical Technology

JUNE 11, 2025

The US Food and Drug Administration (FDA) has placed a clinical hold on several of Gilead’s trials evaluating two HIV treatment candidates, though the rest of the drugmaker’s diverse pipeline remains unaffected. Gilead is considered the leading big pharma in HIV treatments. Shares in Nasdaq-listed Gilead opened 0.3%

HIV Treatment and Prevention Agents 52

HIV Treatment and Prevention Agents FDA Communication Hospitals 52

PharmaShots

APRIL 25, 2023

This drug is currently in multiple P-IIa clinical trials and is being evaluated in combination with other antiviral agents for cHBV. ARO-AAT and ARO-APOC3 are among the highest-phase products developing under Arrowhead’s pipeline for the treatment of liver diseases. R&D Expenditure: $85.1M R&D Expenditure: $437.9M

HIV Treatment and Prevention Agents 40

HIV Treatment and Prevention Agents Packaging Immunization Vaccines 40

ISPE

JULY 6, 2023

1 , 4 A Retrospective Journey In 2015, Vertex’s Orkambi was the first approved drug produced under a CM process for the treatment of cystic fibrosis. Pharma Investment Trend Report: What We’re Watching in 2023.” Published 13 January 2023. Updated 10 January 2023. This is demonstrated by the rise from $1.05 Zydney, and J.

HIV Treatment and Prevention Agents 52

HIV Treatment and Prevention Agents Dosage Pharmaceutical Companies Pharmaceutical Companies 52